Dose optimization in 3D pulsed dose rate brachytherapy for patients with locally advanced cervical cancer: A French multicenter phase II trial

CONCLUSION: HR CTV dose was below the target (85Gy) due to low use of parametrial interstitial needles, as the centers did not always have an adequate applicator, or were at the time at the beginning of their learning curve. The 5-year LC rate was improved compared to that of the comparable STIC PDR group (78%) but lower than the retroEMBRACE cohort of GEC ESTRO (89%). The complication rate was higher than in the comparable group of STIC PDR but close to that of retroEMBRACE. Training brachytherapy teams in interstitial implantation or referring patients to referral centers should help improve the therapeutic index of cervical cancer.PMID:34301498 | DOI:10.1016/j.canrad.2021.06.030

Source: Cancer Radiotherapie - July 24, 2021 Category: Cancer & Oncology Authors: C Charra-Brunaud J Salleron I Menoux K Peignaux A Ducassou A Petit P Pommier I Barillot A A Serre L Thomas M Delannes D Thibouw D Antoni S Renard D Peiffert Source Type: research